Story · Colorado
Amgen Earnings Preview: Q2 2026 Expectations and Analyst Outlook
Amgen Inc. (AMGN) is scheduled to report its Q2 2026 earnings on August 5, 2026, after market close. Analysts expect diluted EPS of $5.57, down 7.5% year-over-year from $6.02. The company has beaten EPS estimates in each of the past four quarters. For fiscal 2026, EPS is projected at $22.31, up 2.2% from fiscal 2025. AMGN stock has gained 22.8% over the past 52 weeks, outperforming the S&P 500 and the healthcare sector ETF. A recent federal judge blocked Colorado's plan to impose a 70% price cap on Amgen's drug Enbrel, removing a key pricing risk. Analysts rate the stock a 'Moderate Buy' with a consensus price target of $360.90 and a street-high target of $427, implying 18.3% upside.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection